Lilly's Van Naarden: Nothing is off the table for dealmaking

• Lilly presented positive data for novel targeted therapies in bladder cancer, early-stage lung cancer, and myeloma at ASCO.
• The company is actively pursuing M&A, with a 'two-pronged strategy' involving early-stage, low-cost deals and de-risked, higher-cost acquisitions with clinical data.
• Lilly sees oncology as a major growth driver alongside its weight loss business, with potential for eight new cancer medicines or significant label expansions.
• The company is also expanding into new therapeutic areas like infectious diseases, leveraging its financial strength for strategic growth.

Jake Van Naarden, Lilly's President of Oncology and Head of Corporate Development, discusses the company's robust oncology pipeline and active M&A strategy. He highlights recent positive data presentations and a 'generational opportunity' to deploy capital across various therapeutic areas, including infectious diseases, with 'nothing off the table' for future dealmaking.